Vector Science and Therapeutics Corp. Enters Into an Investor Relations Agreement and Grants Options
RedChip will provide investor relations services for Vector and can buy up to 150,000 shares at C$1.80 each, pending TSXV approval.
- On August 24, 2026, Vector Science and Therapeutics Corp. entered an investor relations agreement with RedChip Companies, Inc. through principal Dave Gentry, establishing a 12-month partnership term.
- Under the agreement terms, Vector granted RedChip 150,000 stock options at C$1.80 per share and committed to pay US$8,500 monthly in advance for investor relations services.
- RedChip will assist Vector with investor outreach, analyst communications, and perfecting investor collateral and website disclosures in accordance with TSX Venture Exchange policies.
- The engagement remains subject to approval by the TSX Venture Exchange, where Vector trades under the symbol PAIN on the exchange.
- Vector cautions that future operations depend on regulatory approvals; securities have not been registered under the United States Securities Act of 1933.
35 Articles
35 Articles
Vector Science and Therapeutics Corp. Enters Into an Investor Relations Agreement and Grants Options
MEQUON, Wis., Aug. 25, 2026 /PRNewswire/ -- Vector Science and Therapeutics Corp. (TSXV: PAIN) ("Vector" or the "Company") is pleased to announce that the Company has entered into an investor relations agreement (the "IR Agreement") with RedChip Companies, Inc. ("RedChip")…
Vector Science and Therapeutics Corp. Enters Into an Investor Relations Agreement and Grants Options - PressReach
MEQUON, Wis., Aug. 25, 2026 /PRNewswire/ — Vector Science and Therapeutics Corp. (TSXV: PAIN) (“Vector” or the “Company“) is pleased to announce that the Company has entered into an investor relations agreement (the “IR Agreement“) with RedChip Companies, Inc. (“RedChip“) through its principal, Dave Gentry, dated August 24, 2026. The IR Agreement has a twelve-month term and may be renewed or otherwise amended and agreed to in writing by the par…
Coverage Details
Bias Distribution
- 85% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
